65 results about "Esophagus Carcinoma" patented technology

Pharmaceutical composition comprising antibodies or antigen binding fragments thereof that bind to SSEA-4 are disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as those in brain, lung, breast, mouse, esophagus, stomach, liver, bile duct, pancreas, colon, kidney, cervix, ovary, and / or prostate cancer.

The present invention provides antibodies useful as therapeutics for treating and / or preventing diseases associated with cells expressing GT468, including tumor-related diseases such as breast Cancer, lung Cancer, gastric Cancer, ovarian Cancer, hepatocellular Cancer, colon Cancer, pancreatic Cancer, esophageal Cancer, head & neck Cancer, kidney Cancer, in particular renal cell Carcinoma, prostate Cancer, liver cancer, melanoma, sarcoma, myeloma, neuroblastoma, placental choriocarcinoma, cervical cancer, and thyroid Cancer, and the metastatic forms thereof. In one embodiment, the rumor disease is metastatic cancer in the lung.

Pharmaceutical composition comprising antibodies or antigen binding fragments thereof that bind to stage-specific embryonic antigen 4 (SSEA-4) are disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as breast cancer, lung cancer, esophageal cancer, rectal cancer, biliary cancer, liver cancer, buccal cancer, gastric cancer, colon cancer, nasopharyngeal cancer, kidney cancer, prostate cancer, ovarian cancer, cervical cancer, endometrial cancer, pancreatic cancer, testicular cancer, bladder cancer, head and neck cancer, oral cancer, neuroendocrine cancer, adrenal cancer, thyroid cancer, bone cancer, skin cancer, basal cell carcinoma, squamous cell carcinoma, melanoma, and / or brain tumor.

The invention features a method for treating cancer by administering a double-stranded nucleic acid molecule against a CX gene selected from the group consisting of C14orf78, MYBL2, UBE2S and UBE2T. The invention also features products, including the double-stranded nucleic acid molecules and vectors encoding them, as well as compositions comprising the molecules or vectors, useful in the provided methods. The methods of the invention are suited for the treatment of cancers including lung cancer, breast cancer, bladder cancer, esophagus cancer, prostate cancer, cholangiocellular carcinoma and testicular seminoma.

The present invention provides antibodies useful as therapeutics for treating and / or preventing diseases associated with cells expressing GT468, including tumor-related diseases such as breast cancer, lung cancer, gastric cancer, ovarian cancer, hepatocellular cancer, colon cancer, pancreatic cancer, esophageal cancer, head & neck cancer, kidney cancer, in particular renal cell carcinoma, prostate cancer, liver cancer, melanoma, sarcoma, myeloma, neuroblastoma, placental choriocarcinoma, cervical cancer, and thyroid cancer, and the metastatic forms thereof. In one embodiment, the tumor disease is metastatic cancer in the lung.

The present invention discloses a medicine for preventing and curing carcinoma of esophagus and carcinoma of stomach with obvious therapeutic effect. It is made up by using 13 Chinese medicinal materials of isatis leaf, ganoderma, cordyceps, saffron, coptis root and others through a certain preparation process.

The invention discloses a traditional Chinese medicine composition for treating esophagus cancer. The traditional Chinese medicine composition mainly comprises pseudo-ginseng, solanum lyratum, hairyvein agrimony, edible tulip, rhizoma bletillae, oldenlandia diffusa, sculellaria barbata, asparagus cochinchinensis, rhizoma dioscoreae, flos sophorae, subprostrate sophora, rhizoma corydalis, bighead atractylodes rhizome, rhizoma curcumae longae and dried alum. The traditional Chinese medicine composition has a remarkable treatment effect for the esophagus cancer and has the effects of relieving pain, stopping bleeding and resisting cancers and tumors; the rhizoma dioscoreae in the prescription has a good opsonization effect for cancer patients subjected to chemoradiotherapy or operative treatment; and most of local common cheap herbs are selected and used, so that the economic burden on the patients is reduced.

The present invention relates to the use of a compound of formula 3 or a salt thereof for preparing a medicament or a phototherapeutic agent for the treatment of the following diseases, including: acne; AIDS; viral hepatitis; diabetic retinopathy; atypical pneumonia virus infection; coronary Arterial stenosis; carotid artery stenosis; intermittent claudication; Asian (chicken) avian influenza virus infection; cervical dysplasia or various cancers including: blood cancer, cervical cancer, nasopharyngeal cancer, tracheal cancer, laryngeal cancer, bronchial cancer , bronchiolar cancer, bladder cancer, esophagus cancer, stomach cancer, rectal cancer, colon cancer, prostate cancer, hollow organ cancer, bile duct cancer, urinary duct cancer, kidney cancer, uterine cancer, vaginal cancer and other gynecological adnexal cancers. The present invention also relates to methods of treating the above diseases. The present invention further relates to the use of a compound of formula 3 or a salt thereof for the preparation of a photodiagnostic agent for the detection of the above-mentioned diseases and diseases including: atherosclerosis, multiple sclerosis, diabetes, arthritis, rheumatism Arthritis, fungal infection, viral infection, chlamydia infection, bacterial infection, or parasitic infection, HIV infection, hepatitis, herpes simplex, shingles, psoriasis, cardiovascular disease and skin disease. The present invention also relates to methods of detecting the above diseases using photodiagnostic agents. The present invention further relates to a method of cryogenically sterilizing a surgical device or other device, comprising the steps of: providing a compound of formula 3 or a salt thereof on the device; subjecting the device to radiation treatment or sonication. The present invention further relates to a compound of formula 3 or a salt thereof linked or attached to a magnetic element. This compound acts as an MRI enhancer. The present invention also relates to the use of such MRI enhancers for performing MRI scans.

Isolated peptides derived from SEQ ID NO: 21 and fragments thereof that bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL) and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines, are described herein. The inventive peptides encompass both the above mentioned amino acid sequences and modified versions thereof, in which one, two, or several amino acids are substituted, deleted, inserted or added, provided such modified versions retain the requisite HLA binding and / or CTL inducibility of the original sequences. Further provided are nucleic acids encoding any of the aforementioned peptides as well as pharmaceutical agents, substances and / or compositions that include or incorporate any of the aforementioned peptides or nucleic acids. The peptides, nucleic acids, pharmaceutical agents, substances and compositions of this invention find particular utility in the treatment of cancers and tumors, including, for example, AML, bladder cancer, breast cancer, cervical cancer, cholangiocellular carcinoma, CML, colorectal cancer, esophagus cancer, gastric cancer, gastric diffuse-type cancer, lung cancer, lymphoma, prostate cancer, SCLC and soft tissue tumor.

The invention relates to a mussel adhesive protein (MAP) and an application thereof in inhibiting catarrh, and specifically, to applications of a MAP or a product thereof in oral mucositis, rhinitis, otitis media, pharyngitis, laryngitis, bronchitis, esophagitis, gastritis, enteritis, cervicitis, endomyometritis, inflammation resulting from inhalation injury, and oral cavity cancer, nasopharyngeal cancer, carcinoma of middle ear, conjunctival cancer, laryngeal cancer, lung cancer, esophageal cancer, stomach cancer, bowel cancer, cervical cancer, endometrial cancer, and other cancers resulting from the inflammation. The MAP can inhibit symptoms such as flush, fever, swell, and pain owing to catarrh, facilitating healing, relieving itch and pain, and having broad applications in the fields of medicines, cosmetics, medical products, disinfection products, healthcare products, foods, and household goods.

The present invention relates to a Chinese medicine composition and its preparation process. In particular, it relates to a Chinese medicine prescription for curing the malignant tumor of digestive tract, including carcinoma of stomach, cardiac cancer, carcinoma of esophagus and rectal cancer, etc. and its preparation process. It can be made into dripping pills and soft capsule preparation.

The invention belongs to the field of medicinal chemistry, and particularly relates to phosphoglyceromutase 1. The invention provides an inhibitor of the phosphoglyceromutase 1; a specific structure is as shown in the formula I as shown in the description. The invention further provides a synthesis method of the structure as shown in the formula I as shown in the description and application in diseases related to cell apoptosis and tumors thereof; the diseases include various kinds of cancer of stomach cancer, liver cancer, myelomas, bladder cancer, prostatic cancer, breast cancer, rectal cancer, head and neck cancer, lung cancer, melanomas, ovarian cancer, cervical cancer, esophagus cancer and the like.

A temozolomide sustained release implant for treating solid tumors is characterized in that the sustained release implant includes effective dose of anticancer temozolomide, sustained release excipients and a certain quantity of sustained release moderator. Solid tumors include pancreatic cancer, lung cancer, liver cancer, breast cancer, cerebroma, ovarian cancer, prostatic carcinoma, esophageal carcinoma, lymphadenoma, osteosarcoma and colorectal cancer. Sustained release excipients mainly are one or combination of copolymer of glycolic acid and hydroxyacetic acid, polifeprosan, and poly(L-lactide-co-ethyl phosphate); in the process of decompression, temozolomide can be slowly released to local tumor, thus maintaining effective drug concentration of local tumor as well as significantly reducing overall toxic reaction. Being placed in local tumor, the sustained release implant not only reduces overall toxic reaction of temozolomide, but also selectively improves drug concentration in local tumor, enhancing the therapeutic effects of non-operative therapy such as chemotherapy drugs and radiotherapy.

The invention relates to a medicinal composition and method for preparation, wherein the medicinal composition is prepared from astragalus root, gen-seng, flavescent sophora root through supersonic extracting, alcohol depositing, water depositing, formulating, loading and freeze-drying. The composition can be used for treating primary liver cancer, lung carcinoma, esophagus cancer, restocarcinoma, malignant lymphoma, gynaecologic carcinoma, leucopenia and chronic hepatitis B.

The invention discloses a traditional Chinese medicine composition for treating esophagus cancer. The traditional Chinese medicine composition mainly comprises pseudo-ginseng, solanum lyratum, hairyvein agrimony, edible tulip, rhizoma bletillae, oldenlandia diffusa, sculellaria barbata, asparagus cochinchinensis, rhizoma dioscoreae, flos sophorae, subprostrate sophora, rhizoma corydalis, bighead atractylodes rhizome, rhizoma curcumae longae and dried alum. The traditional Chinese medicine composition has a remarkable treatment effect for the esophagus cancer and has the effects of relieving pain, stopping bleeding and resisting cancers and tumors; the rhizoma dioscoreae in the prescription has a good opsonization effect for cancer patients subjected to chemoradiotherapy or operative treatment; and most of local common cheap herbs are selected and used, so that the economic burden on the patients is reduced.

The invention discloses a traditional Chinese medicine composition for treatment of cancers. The traditional Chinese medicine composition is prepared by medicinal materials of rhaphiolepis indica, podophyllum, gamboge, fructus camptothecae acuminatae, a wall snake, Artemisia apiacea, peppers, radix ophiopogonis, cynomorium songaricum, sealwort and the like. The traditional Chinese medicine composition has remarkable treatment effect on the various types of cancers of lung cancer, liver cancer, breast cancer, gastric cancer, lymph cancer, intestinal cancer, esophagus cancer, kidney cancer, bladder cancer, pancreatic cancer, melanoma, uterine cancer and the like.

The invention relates to the nucleic acid and polypeptide sequences of three novel human Ron-related gene variants (Ron-V1, Ron-V2, and Ron-V3). The invention also provides a process for producing the polypeptides of the variants, as well as uses for the nucleic acid, polypeptide and antibodies to same in diagnosing human breast carcinoma, breast adenocarcinoma, cervix epidermoid carcinoma, cervix epitheloid carcinoma, colon adenocarcinoma, urinary bladder carcinoma, prostate carcinoma, esophagus epidermoid carcinoma and esophagus carcinoma.

The present invention relates to siRNA field, and discloses the application of siRNA suppressing human Ezrin gene expression in the research on esophagus carcinoma cell proliferation. The present invention designs and synthesizes two pairs of siRNA's targeting human Ezrin gene, and constitutes the expression vector for them to express inside mammal cell successfully. These siRNA's can interfere the expression of Ezrin gene effectively and specifically, and esophagus carcinoma cell strain with lower Ezrin expression is established. The present invention lays foundation for the deep research on the function of Ezrin in esophagus carcinoma and other Ezrin related tumors. The present invention researches the relationship between Ezrin and the generation, development and cleaving proliferation of esophagus carcinoma, and lays foundation for revealing the pathogenesis of esophagus carcinoma and treating esophagus carcinoma.